MaxCyte Inc Cash Flow Conversion Efficiency
MaxCyte Inc cash flow conversion efficiency. Based on the latest financial reports, MaxCyte Inc (MXCT) has a cash flow conversion efficiency ratio of -0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.46 Million) by net assets ($180.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MaxCyte Inc (2012–2024)
Cash flow conversion efficiency of MaxCyte Inc from 2012 to 2024. This chart illustrates how MaxCyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MaxCyte Inc share price for real-time trading data and today's change.
MaxCyte Inc Cash Flow Conversion Ratio Explained
MaxCyte Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MaxCyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MaxCyte Inc ranked by their cash flow conversion efficiency. Also see how much is MaxCyte Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ilyang Pharm
KO:007570
|
0.009x |
|
AnaPass Inc
KQ:123860
|
-0.004x |
|
Krystal Integrated Services Ltd
NSE:KRYSTAL
|
-0.026x |
|
Berenson Acquisition Corp I
NYSE MKT:BACA
|
1.396x |
|
Méliuz S.A
SA:CASH3
|
0.050x |
|
Rorze Systems Corporation
KQ:071280
|
0.008x |
|
Ispire Technology Inc. Common Stock
NASDAQ:ISPR
|
-0.121x |
|
Peace Acquisition Corp Ordinary Shares
NASDAQ:PECE
|
-0.003x |
Annual Cash Flow Conversion Efficiency for MaxCyte Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of MaxCyte Inc from 2012 to 2024. Review MXCT cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $206.25 Million | $-27.61 Million | -0.134x | -43.31% |
| 2023-12-31 | $232.17 Million | $-21.69 Million | -0.093x | -60.47% |
| 2022-12-31 | $253.97 Million | $-14.78 Million | -0.058x | -43.29% |
| 2021-12-31 | $262.90 Million | $-10.68 Million | -0.041x | +84.63% |
| 2020-12-31 | $33.23 Million | $-8.78 Million | -0.264x | +59.16% |
| 2019-12-31 | $13.60 Million | $-8.80 Million | -0.647x | +24.21% |
| 2018-12-31 | $12.28 Million | $-10.49 Million | -0.854x | -72.92% |
| 2017-12-31 | $19.60 Million | $-9.68 Million | -0.494x | -7.51% |
| 2016-12-31 | $5.08 Million | $-2.33 Million | -0.459x | -884.44% |
| 2015-12-31 | $-3.08 Million | $-180.50K | 0.059x | -94.99% |
| 2014-12-31 | $-1.65 Million | $-1.93 Million | 1.169x | +223.42% |
| 2013-12-31 | $-1.54 Million | $-557.80K | 0.361x | -89.96% |
| 2012-12-31 | $-590.70K | $-2.13 Million | 3.599x | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more